Innovation Success



Innovation Success

Unsuccessful Innovation - Vorapaxar Cholesterol Drug

One of the largest pharmaceutical companies known in the word is the Merck & Co., Inc, also known as Merck Sharp & Dohme or MSD. It is one of the seven biggest pharmaceutical companies both by market capitalization and revenue all over the world nowadays. It researches, discovers, improves and develops, manufactures and sells a wide range of pharmaceutical products to contribute to the progress of both human and animal health. On the other hand, anti-coagulants or anti-clotting drugs are those agents that prevent blood clots build up. Recent findings regarding the trial of the newly developed product, specifically an anti-clotting drug, of Merck Pharmaceutical Company had failed.

It is supposedly aiming in preventing different heart ailments, strokes, blood vessel disorders and any cases related to the clogging of arteries. Angina pectoris or severe chest pain as well as myocardial infarction (death of heart tissues) is also included in the different diseases that this drug is supposed to prevent and treat. The drug, vorapaxar, (vor-uh-PACKS'-ar), rendered no significant benefit when it was added to standard medicines in a study of 13,000 patients around the world. In fact, it was found out to increase the risk of serious bleeding. Instead of the expected desired effect of the anti-clotting drug, it turned out to be the opposite of which. Merck's official representative said that “results due out early next year from another large study testing the drug in different types of patients, will tell more about its potential”.

Successful Innovation - Statins Cholesterol Drug

Atorvastatin is a successful drug for the cure of cholesterol. This drug is prepared by one of the leading pharmaceutical companies of the world, named Pfizer. The drug has proved to be effective in managing hypercholesterolemia and preventing the occurrence of atherosclerotic ...